titioner's Docket No. MPI01-018P1RNM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MART	tet No. MPI01-018P1RNM		PATENT CONTRACTOR OF THE PATENT
In re application of:	THE UNITED STATES PA	·	- Carry Va
Application No.:	10/074,527	Group No.:	1652
Filed:	February 12, 2002	Examiner:	N/A
For:	33945, A HUMAN GLYC THEREFOR	OSYLTRANSFERASI	E FAMILY MEMBER AND USES

Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

The supplemental information disclosure statement submitted herewith is being filed:

(x) Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

[] After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

× deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

× with sufficient postage as first class mail. as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: October 20, 2003 Sean Hunziker/Carolyn Willey

(type or print name of person certifying)

*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

Willefiever occ	curs mst.	• •
_	anying this transmittal is the fee set forth in 37 C.F.R. S disclosure statement under Section 1.97(c). (\$180.00).	ection 1.17(p) for submission of a
in a communic	m of information contained in the supplemental informatication from a foreign patent office in a counterpart fore to the filing of the information disclosure statement. 37	eign application not more than three
communicati knowledge o to any indivi	n of information contained in the information disclution from a foreign patent office in a counterpart for of the person signing the statement after making residual designated in Section 1.56(c) more than threation disclosure statement. 37 C.F.R. Section 1.97(c)	oreign application and to the casonable inquiry, was known e months prior to the filing of
	OR	
Section 1.113	rmation disclosure statement transmitted herewith is be 3, or a notice of allowance under Section 1.311, whi sly with, the payment of the issue fee.	eing filed after a final action under chever occurs first, but before, or
() In accorda	lance with the requirements of 37 C.F.R. Section 1.97(d	1):
A. []	Accompanying this transmittal is the fee set fort submission of an information disclosure statement under	
	munication from a foreign patent office in a counterpar onths prior to the filing of the information disclosi	t foreign application not more than
knowledge individual	No item of information contained in the information in the information from a foreign patent office in a counterpage of the person signing the statement after making real designated in Section 1.56(c) more than three making disclosure statement 37 C.F.R. Section 1.97(e)(2)	part foreign application and to the sonable inquiry, was known to any nonths prior to the filing of the

FEE PAYMENT

3. () The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

(x)	A _I	oplicant believes no fee is due in connection with this submission.
-		Fee due \$0.00
		METHOD OF PAYMENT OF FEE
4.	()	Attached is a check in the amount of \$
	. ()	Charge Account No. 501668 in the amount of \$0.00 .
	()	A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

MILLENNIUM PHARMACEUTICALS, INC.

By

Millennium Pharmaceuticals, Inc.

Tracy M. Sioussat, Ph.D.

Registration No. 50,609

75 Sidney Street

Cambridge, MA 02139 Telephone - 617-374-7679 Facsimile - 617-551-8820

titioner's Docket No. MPI01-018P1RNM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Peter J. Olandt, Rachel E. Meyers and Katherine M. Galvin

Application No.:

10/074,527

Group No.:

1652

Filed:

February 12, 2002

Examiner:

Rao, Manunath N.

For:

TECH CENTER SOOS 33945, A HUMAN GLYCOSYLTRANSFERASE FAMILY MEMBER AND USES

THEREFOR

Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Supplemental Information Disclosure Statement

The following sections are being submitted for this Supplemental Information Disclosure Statement:

- 1. (x) **Preliminary Statements**
- 2. Forms PTO/SB/08A and 08B (substitute for Form PTO-1449)
- 3. Copies of Listed Information Items Accompanying This Statement
- 4. Copy of International Search Report.

Preliminary statements

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

× deposited with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

× with sufficient postage as first class mail. as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: October 20, 2003

Sean Hunziker/Carolyn Willey

(type or print name of person certifying)

*WARNING:Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this supplemental information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this supplemental information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) accompany this information statement.

October 20, 2003	MILLENNIUM PHARMACEUTICALS, INC.	, i
	By Try M. houset	
	Tracy M. Sioussat, Ph.D.	
	Registration No. 50,609	
	75 Sidney Street	•
	Cambridge, MA 02139	
	Telephone - 617-374-7679	
	Facsimile - 617-551-8820	

Please type a plus sign (+) inside this box + Under the Paperwork Reduction Act of 1995, no persons are required to res	Patent and Trademark Office		0654-0031 DMMERCE
OCT 2 4 2003	Сотр	plete if Known	7
Substitute for forth 1449A/PTO			2 ` Q
WHEORMATION DISCLOSURE	Applicati n Number	10/074,527	
	Filing Date	February 12, 2002	4
STATEMENT BY APPLICANT	First Nam d Inv nt r	Peter J. Olandt, et. al	وح .
	Group Art Unit	1652	, 63
(use as many sheets as necessary)	Examiner Name	Rao, Manjunath N.	22
Sheet 1 of 1	Attorney Docket Number	MPI01-018P1RNM	02

*************************************		<u> </u>	•	U.S. PATENT DOCUME	NTC	<u> </u>
Examiner Initials*	Cite No.1	*	ocument nd Code ² known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
* . * **	A1	5,871,990		Henrik Clausen and Eric Paul Benett	02-16-1999	
	A2	5,910,570		Pharmacia & Upjohn Company	06-08-1999	
**						
				1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
•						
		\$				<u> </u>
· .						
<u> </u>	• • •					
<u> </u>						

FOREIGN PATENT DOCUMENTS									
Examiner	Cite	For	eign Patent Do		Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where	-6	
Initials*	No.'	Office ³	Number ⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document (MM-DD-YYYY)	Relevant Passages or Relevant Figures Appear	T	
						<u> </u>			
								1	

	and the second second second					<u> </u>	the same and the s
Examiner		,		*	Date		
Signature			 ·		Considered		<u> </u>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸Applicant is to place a check mark here if English language Translation is attached.



Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

	- cons	Complete if Known	7
Inder the Paperwork Reduction Act of 1995, no be	rsons are required to respond to a c	collection of information unless it contains a valid OMB control number.	<u> </u>
·	IPE	Patent and Trademark Office: U.S. DEPARTMENT OF	
		Approved for use through 10/31/99. Of	MB 0654-0031
Please type a plus sign (+) inside this box	\longleftrightarrow	PTO/SI	B/08B (10-96)

(use as many sheets as necessary) Group Art Unit 1652 Examiner Name Rao, Manjunath N.	Substitute	e for form 1449B/PTC) (g	OCT 2 4 2003	Com	plete if Known	780
STATEMENT BY APPLICANT First Named Invent r Peter J. Olandt, et. al. Group Art Unit 1652 Examiner Name Rao, Manjunath N.	INFC	DRMATION	ΙΠ̈́́	SCI OSIIŽE	Applicati n Number	10/074,527	Cx (
(use as many sheets as necessary) Group Art Unit Examiner Name Rao, Manjunath N.	II VI C			A ACCOUNTIL	Filing Dat	February 12, 2002	.,2
(use as many sheets as necessary) Group Art Unit Examiner Name Rao, Manjunath N.	STA	TEMENT E	3Y A		First Named Invent r	Peter J. Olandt, et. al.	7
					Group Art Unit	1652	300
Sheet 1 of 1 Attorney Docket Number MPI01-018P1RNM		(use as many s	sheets a	s necessary)	Examiner Name	Rao, Manjunath N.	72
	Sheet	1	of	1	Attorney Docket Number	MPI01-018P1RNM	90n

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.
•	C5	White, Thayer et al. "Purification and cDNA Cloning of a Human UDP- <i>N</i> -acetyla-α-D-galactosamine:polypeptide <i>N</i> -Acetylgalactosaminyltransferase" <i>The Journal of Biological Chemistry</i> Vol. 270, No. 41, (October 13, 1995) pp. 24156-24165.

	<u> </u>			the state of the s
Examiner		· .	Date	
Signature			Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here is English language Translation is attached.